| Dr Jason Robert Determann, MD | |
|
341 Greeno Rd N, Fairhope, AL 36532-2979 | |
| (251) 928-2401 | |
| (251) 928-5099 |
| Full Name | Dr Jason Robert Determann |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 10 Years |
| Location | 341 Greeno Rd N, Fairhope, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255566311 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | 30613 (Alabama) | Secondary |
| 207X00000X | Orthopaedic Surgery | 30613 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South Baldwin Regional Medical Center | Foley, AL | Hospital |
| Thomas Hospital | Fairhope, AL | Hospital |
| D W Mcmillan Memorial Hospital | Brewton, AL | Hospital |
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Imc -gulf Orthopaedics Llc | 6204236946 | 33 |
News Archive
Ovarian cancer is the most lethal gynecologic malignancy in the United States, resulting in an estimated 14,100 deaths and 22,500 new cases in 2017 alone. This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.
GenVec today reported that encouraging preclinical findings on a novel approach to treating hearing loss have been published in the March 2005 issue of Nature Medicine.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
› Verified 7 days ago
| Entity Name | Bayside Orthopedic & Rehabilitation Center Pc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215014097 PECOS PAC ID: 3779561410 Enrollment ID: O20040709000846 |
News Archive
Ovarian cancer is the most lethal gynecologic malignancy in the United States, resulting in an estimated 14,100 deaths and 22,500 new cases in 2017 alone. This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.
GenVec today reported that encouraging preclinical findings on a novel approach to treating hearing loss have been published in the March 2005 issue of Nature Medicine.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
› Verified 7 days ago
| Entity Name | Imc -gulf Orthopaedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639753171 PECOS PAC ID: 6204236946 Enrollment ID: O20210616003444 |
News Archive
Ovarian cancer is the most lethal gynecologic malignancy in the United States, resulting in an estimated 14,100 deaths and 22,500 new cases in 2017 alone. This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.
GenVec today reported that encouraging preclinical findings on a novel approach to treating hearing loss have been published in the March 2005 issue of Nature Medicine.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
› Verified 7 days ago
| Entity Name | Southern Orthopaedic Alliance Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588364228 PECOS PAC ID: 2365800604 Enrollment ID: O20230620001264 |
News Archive
Ovarian cancer is the most lethal gynecologic malignancy in the United States, resulting in an estimated 14,100 deaths and 22,500 new cases in 2017 alone. This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.
GenVec today reported that encouraging preclinical findings on a novel approach to treating hearing loss have been published in the March 2005 issue of Nature Medicine.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Robert Determann, MD Po Box 1186, Fairhope, AL 36533-1186 Ph: (251) 928-2401 | Dr Jason Robert Determann, MD 341 Greeno Rd N, Fairhope, AL 36532-2979 Ph: (251) 928-2401 |
News Archive
Ovarian cancer is the most lethal gynecologic malignancy in the United States, resulting in an estimated 14,100 deaths and 22,500 new cases in 2017 alone. This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.
GenVec today reported that encouraging preclinical findings on a novel approach to treating hearing loss have been published in the March 2005 issue of Nature Medicine.
A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
› Verified 7 days ago
John A Rodriguez-feo, MD Orthopedic Surgery Medicare: May Accept Medicare Assignments Practice Location: 912 Plantation Blvd, Fairhope, AL 36532 Phone: 251-928-4033 Fax: 251-928-4032 | |
Dr. Carl E. Albertson, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 341 Greeno Rd N, Fairhope, AL 36532 Phone: 251-928-2401 Fax: 251-928-5099 | |
Dr. Trevor Malcolm Stubbs, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 341 Greeno Rd N, Fairhope, AL 36532 Phone: 251-928-2401 Fax: 251-928-5099 | |
Dr. Albert Jameson Savage Iv, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 341 Greeno Rd N, Fairhope, AL 36532 Phone: 251-928-2401 Fax: 251-928-5099 | |
Dr. Paul Hoke Fellers Jr., M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 19195 Scenic Highway 98, Fairhope, AL 36532 Phone: 251-928-1929 | |
Dr. Joey Franklin Carter, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 341 Greeno Rd N, Fairhope, AL 36532 Phone: 251-928-2401 Fax: 251-928-5099 |